Human osteoclast-derived cathepsin

Details Human osteoclast-derived cathepsin Human osteoclast-derived cathepsin

1997-02-12

2002-07-23

Prouty, Rebecca E. (Department: 1652)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving hydrolase

C435S219000, C435S226000, C435S004000, C435S183000

Reexamination Certificate

active

06423507

ABSTRACT:

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a human osteoclast-derived cathepsin (Cathepsin O). The invention also relates to inhibiting the action of such polypeptide and to assays for identifying inhibitors of the polypeptide.
Bone resorption involves the simultaneous removal of both the mineral and the organic constituents of the extracellular matrix. This occurs mainly in an acidic phagolysosome-like extracellular compartment covered by the ruffled border of osteoclasts. Barron, et al., J. Cell Biol., 101:2210-22, (1985). Osteoclasts are multinucleate giant cells that play key roles in bone resorption. Attached to the bone surface, osteoclasts produce an acidic microenvironment between osteoclasts and bone matrix. In this acidic microenvironment, bone minerals and organic components are solubilized. Organic components, mainly type-I collagen, are thought to be solubilized by protease digestion. There is evidence that cysteine proteinases may play an important role in the degradation of organic components of bone. Among cysteine proteinases, cathepsins B, L, N, and S can degrade type-I collagen in the acidic condition. Etherington, D. J. Biochem. J., 127, 685-692 (1972). Cathepsin L is the most active of the lysosomal cysteine proteases with regard to its ability to hydrolyze azocasein, elastin, and collagen.
Cathepsins are proteases that function in the normal physiological as well as pathological degradation of connective tissue. Cathepsins play a major role in intracellular protein degradation and turnover, bone remodeling, and prohormone activation. Marx, J. L., Science. 235:285-286 (1987). Cathepsin B, H, L and S are ubiquitously expressed lysosomal cysteine proteinases that belong to the papain superfamily. They are found at constitutive levels in many tissues in the human including kidney, liver, lung and spleen. Some pathological roles of cathepsins include an involvement in glomerulonephritis, arthritis, and cancer metastasis. Sloan, B. F., and Honn, K. V., Cancer Metastasis Rev., 3:249-263 (1984). Greatly elevated levels of cathepsin L and B mRNA and protein are seen in tumor cells. Cathepsin L mRNA is also induced in fibroblasts treated with tumor promoting agents and growth factors. Kane, S. E. and Gottesman, M. M. Cancer Biology, 1:127-136 (1990).
In vitro studies on bone resorption have shown that cathepsins L and B may be involved in the remodelling of this tissue. These lysosomal cysteine proteases digest extracellular matrix proteins such as elastin, laminin, and type I collagen under acidic conditions. Osteoclast cells require this activity to degrade the organic matrix prior to bone regeneration accomplished by osteoblasts. Several natural and synthetic inhibitors of cysteine proteinases have been effective in inhibiting the degradation of this matrix.
The isolation of cathepsins and their role in bone resorption has been the subject of an intensive study. OC-2 has recently been isolated from pure osteoclasts from rabbit bones. The OC-2 was found to encode a possible cysteine proteinase structurally related to cathepsins L and S. Tezuka, K., et al., J. Biol. Chem., 269:1106-1109, (1994).
An inhibitor of cysteine proteinases and collagenase, Z-Phe-Ala-CHN
2
has been studied for its effect on the resorptive activity of isolated osteoclasts and has been found to inhibit resorption pits in dentine. Delaisse, J. M. et al., Bone, 8:305-313 (1987). Also, the affect of human recombinant cystatin C, a cysteine proteinase inhibitor, on bone resorption in vitro has been evaluated, and has been shown to significantly inhibit bone resorption which has been stimulated by parathyroid hormone. Lerner, U. H. and Grubb Anders, Journal of Bone and Mineral Research, 7:433-439, (1989). Further, a cDNA clone encoding the human cysteine protease cathepsin L has been recombinantly manufactured and expressed at high levels in
E. coli
in a T7 expression system. Recombinant human procathepsin L was successfully expressed at high levels and purified as both procathepsin L and active processed cathepsin L forms. Information about the possible function of the propeptide in cathepsin L folding and/or processing and about the necessity for the light chain of the enzyme for protease activity was obtained by expressing and purifying mutant enzymes carrying structural alterations in these regions. Smith, S. M. and Gottesman, M. M., J. Bio Chem., 264:20487-20495, (1989). There has also been reported the expression of a functional human cathepsin S in
Saccharomyces cerevisiae
and the characterization of the recombinant enzyme. Bromme, D. et al., J. Bio Chem., 268:4832-4838 (1993).
In accordance with one aspect of the present invention, there is provided a novel mature polypeptide which is a osteoclast-derived cathepsin as well as fragments, analogs and derivatives thereof. The human osteoclast-derived cathepsin of the present invention is of human origin.
In accordance with another aspect of the present invention, there are provided polynucleotides (DNA or RNA) which encode such polypeptides.
In accordance with still another aspect of the present invention, there is provided a procedure for producing such polypeptide by recombinant techniques.
In accordance with yet a further aspect of the present invention, there is provided an antibody which inhibits the action of such polypeptide.
In accordance with yet another aspect of the present invention, there are provided antagonists to such polypeptides, e.g., a small molecule inhibitor which may be used to inhibit the action of such polypeptide, for example, in the treatment of metastatic tumors and osteoporosis.
In accordance with still another aspect of the present invention, there is provided a procedure for developing assay systems to identify inhibitors of the polypeptide of the present invention.
These and other aspects of the present invention should be apparent to those skilled in the art from the teachings


REFERENCES:
patent: 5223408 (1993-06-01), Goeddel et al.
patent: 5312816 (1994-05-01), Spielvogel et al.
patent: 5374623 (1994-12-01), Zimmerman et al.
patent: 5486623 (1996-01-01), Zimmerman et al.
patent: 5501969 (1996-03-01), Hastings
patent: 5552281 (1996-09-01), Stashenko et al.
patent: 5624801 (1997-04-01), Stashenko et al.
patent: 5656728 (1997-08-01), Stashenko et al.
patent: 5736357 (1998-04-01), Brömme
patent: 0 104 920 (1992-03-01), None
patent: 0 110 674 (1992-06-01), None
patent: 0 111 129 (1992-07-01), None
patent: 0 504 938 (1992-09-01), None
patent: 520427 (1992-12-01), None
patent: 525420 (1993-02-01), None
patent: 91/01378 (1991-02-01), None
patent: 94/23033 (1994-10-01), None
patent: 95/24182 (1995-09-01), None
patent: 96/13523 (1996-05-01), None
patent: 97/35971 (1997-10-01), None
patent: WO 97/47642 (1997-12-01), None
patent: 98/00716 (1998-01-01), None
patent: 98/03651 (1998-01-01), None
patent: WO 98/08494 (1998-03-01), None
patent: 98/20024 (1998-05-01), None
patent: 98/20156 (1998-05-01), None
patent: 98/34117 (1998-08-01), None
J. of Biological Chemistry, vol. 269, No. 2, pp. 1106-1109 (Jan. 14, 1994).
Science, vol. 239, pp. 1288-1291 (Mar. 11, 1988).
J. of Histochemistry & Cytochemistry, vol. 41, No. 7, pp. 1075-1083 (1993).
Histochemistry, vol. 101, pp. 33-40 (1994).
Nature, vol. 299, pp. 592-596 (Oct. 14, 1982).
Histochemistry, vol. 99, pp. 411-414 (1993).
Biochemical & Biophysical Research Communications, vol. 178, No. 1, pp. 178-184 (Jul. 15, 1991).
J. Bone and Mineral, Res. 7:433-439 (1992).
J. Biological Chemistry, vol. 264, pp. 20487-20495 (1989).
J. Biological Chemistry, vol. 268, pp. 4832-4839 (1993).
Seminars in Cancer Biology, vol. 1, pp. 127-136 (1995).
Seminars in Cancer Biology, vol. 1, pp. 137-152.
Bone, vol. 8, pp. 305-313 (1987).
J. Biological Chemistry, vol. 264, pp. 20487-20495 (1989).
Liao et al. (1984)Biochem. Biophys. Res. Comm.“Catheps

Affiliated with

Also associated with

Rating

Human osteoclast-derived cathepsin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human osteoclast-derived cathepsin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human osteoclast-derived cathepsin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2900539